Evidence map›Paper›PMID 40516982›Full record

ReviewSeminars in radiation oncology2025

Optimizing Radiation Therapy for Localized Prostate Cancer: Exploring Synergies With Androgen Deprivation Therapy and Novel Systemic Agents.

Krishnan R Patel, Melissa Abel, Spyridon P Basourakos, Deborah E Citrin, Ravi A Madan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Seminars in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Krishnan R PatelRadiation Oncology Branch, National Cancer Institute, Bethesda, MD. Electronic address: Krishnan.R.Patel.MD@gmail.com.
Melissa AbelGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD.
Spyridon P BasourakosDepartment of Urology, Mayo Clinic, Rochester, MN.
Deborah E CitrinRadiation Oncology Branch, National Cancer Institute, Bethesda, MD.
Ravi A MadanGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD.

Funding

Intramural NIH HHS Z99 CA999999NCI NIH HHS Y99 CA999999
6 · The paper itself

Abstract

Although radiation therapy has been used as a curative treatment option for patients with localized prostate cancer for decades, there remains a continued need to improve outcomes for patients with localized disease. Systemic therapy in the form of androgen deprivation therapy (ADT) is an important adjunct to radiation therapy which may serve to improve the curative potential of treatment; however, not all forms of systemic therapy which have demonstrated activity in metastatic prostate cancer will improve outcomes for patients with localized disease. Research into the use of radiation therapy with ADT, androgen receptor signaling inhibitors (ARSIs), chemotherapy, poly(ADP-ribose) polymerase (PARP) inhibitors, immunotherapy, and other small molecule inhibitors is ongoing and will help to define not only which of these may be beneficial for patients localized prostate cancer but also which patients may be optimal candidates to receive these adjunctive therapies.

Indexed as

Androgen AntagonistsProstatic NeoplasmsAndrogen Receptor AntagonistsCombined Modality TherapyHumansImmunotherapyMalePoly(ADP-ribose) Polymerase InhibitorsAndrogen AntagonistsAndrogen Receptor AntagonistsPoly(ADP-ribose) Polymerase Inhibitors

Identifiers

PMID40516982
PMCPMC12169810

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.